分子别名(Synonym)
GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C
表达区间及表达系统(Source)
Mouse GUCY2C, Fc Tag (GUC-M5254) is expressed from human 293 cells (HEK293). It contains AA Val 20 - Met 433 (Accession # Q3UWA6-1).
Predicted N-terminus: Val 20
Request for sequence
蛋白结构(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 73.5 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳(SDS-PAGE)
Mouse GUCY2C, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Mouse GUCY2C, Fc Tag (Cat. No. GUC-M5254) is more than 90% and the molecular weight of this protein is around 195-215 kDa verified by SEC-MALS.
Report
背景(Background)
GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.